MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Transcranial magnetic stimulation study in primary dystonia of presumed genetic etiology

    D. Dhar, A. Bhattacharya, N. Kamble, V. Holla, R. Yadav, B. Muthusamy, P. Pal (Bengaluru, India)

    Objective: To study the neurophysiological parameters in primary dystonia of presumed genetic etiology using transcranial magnetic stimulation (TMS) and correlate with their genotype. Background: The…
  • 2023 International Congress

    Emerging treatments targeting DNA and RNA in Huntington’s disease: a review of future perspectives and current challenges

    G. Lima, F. Sarmento, I. Camargo, R. Saba, S. Silva, V. Borges, H. Ferraz (São Paulo, Brazil)

    Objective: To review the progress made towards the development of a huntingtin (HTT) lowering strategy based on RNA and DNA and also to assess the…
  • 2023 International Congress

    Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: A multicenter cross-sectional study

    R. Morimoto, M. Iijima, Y. Okuma, K. Suzuki, F. Yoshii, S. Nogawa, T. Osada, K. Kitagawa (Tokyo, Japan)

    Objective: We aimed to investigate factors associated with non-motor symptoms (NMS) in Parkinson's disease (PD). Background: PD is characterized by a variety of NMS, such…
  • 2023 International Congress

    Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study

    CY. Yu, WG. Liu, AP. Gong, LH. Shen, H. Huang, Y. Zhao, CF. Liu (nanjing, China)

    Objective: This study aimed to investigate the efficacy and safety comparison between LCE and Pramexol in Chinese PD patients with the wearing-off phenomenon. Background: Wearing…
  • 2023 International Congress

    Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

    M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

    Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…
  • 2023 International Congress

    Validating wearable sensors as an assessment tool for Parkinson’s Disease

    K. Silis, N. Kieran, N. Shawki, S. Madarshahian, M. Serruya, T. Liang (Philadelphia, USA)

    Objective: The objective of our pilot study was to assess the feasibility of using a portable accelerometer system to accurately identify motor findings in patients…
  • 2023 International Congress

    Cognitive function in Parkinson’s disease: associations with perivascular space in basal ganglia

    L. Luo, L. Li, Y. Yin, R. Ren, Y. Yang (Kunming, China)

    Objective: This study investigated the association of enlarged perivascular space (EPVS) and white matter hyperintensity (WMH) with cognitive impairment in Parkinson's disease (PD). Background: Cognitive…
  • 2023 International Congress

    Long-term effects of a mobile technology-based brisk walking program on Parkinsonian symptoms in Parkinson’s disease – a randomized controlled trial

    MKY. Mak, ISK. Wong-Yu (Hong Kong SAR, China)

    Objective: To evaluate the effectiveness of a 6-month mobile technology-based brisk walking program on motor and non-motor symptoms and self-perceived ability in people with Parkinson’s…
  • 2023 International Congress

    Inferring Rigidity Scores in MDS-UPDRS Motor Assessment from Other Items

    F. Duque Quiceno, Y. Dushin, G. Sarapata, S. Komarov, A. Matveev, J. O'Keeffe (London, United Kingdom)

    Objective: This study aimed to explore the possibility of inferring rigidity scores in MDS-UPDRS assessments from other items to enhance the accuracy of clinical evaluations…
  • 2023 International Congress

    Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson’s disease patients with GBA1 mutations

    M. Fonseca, G. Castilla-Fernández, J. Liu, J. Holenz, N. Mendonça, D. Simon (Porto, Portugal)

    Objective: To assess clinical trial sample size estimations under variable simulated scenarios for Parkinson’s disease (PD) patients with mutations in the β-glucocerebrosidade gene (GBA1). Background:…
  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley